CSPC was defined as either Gleason grade group 2 or greater, or grade group 1 with more than 1/3 of total cores positive. Univariate Chi square, logistic regression and receiver operating characteristic (ROC) curve analyses were performed to evaluate the association between PSAD values and CSPC.
INTRODUCTION AND OBJECTIVES:
The aim of this study is to assess the predictors of csPCa in the largest available series of men with PIRADS 3 at mpMRI and to develop and externally validate an individualized risk model that may safely spare prostate biopsies in patients with a low probability to have csPCa.
METHODS: We identified 406 PIRADS 3 patients who underwent mpMRI of the prostate and subsequent targeted and concomitant systematic biopsy at two tertiary care referral Centres between 2013 and 2018. All patients had a negative DRE and they either were biopsy naive or received a previous prostate biopsy. The study outcome was csPCa, defined as Gleason!3þ4 at prostate biopsy. Multivariable logistic regression analysis (MVA) was performed to develop a predictive tool for the study outcome. Predictors included age at biopsy, PSA (ng/ml), prostate volume (ml) and previous biopsy (naive vs. negative vs. positive). The predictive accuracy (PA) was quantified using the AUC and the calibration plot method. Multivariable-derived coefficients were used to develop a novel risk-calculator. External validation of the model was performed into a population of 183 PI-RADS 3 men who underwent targeted and concomitant systematic biopsy at three tertiary care referral Centres between 2013 and 2018, using the regression coefficient and adjusting for the prevalence of the disease.
RESULTS: Overall, 27.0% (110/406) and 10.3% (19/183) patients had csPCa in the development and validation cohort. At MVA, age at biopsy (OR:1.07), PSA (OR:1.08) and prostate volume (OR:0.97) were independent predictors of csPCa (all p 0.001).The multivariable model had a PA of 0.78 and the calibration plot was excellent. A low-risk group having <15% risk of harbouring csPCa was found based on the MVA derived risk calculator. Avoiding prostate biopsies in low-risk group would allow to spare 29% of all biopsies at the cost of missing 6% of csPCa. The sensitivity and negative predictive value associated with 15% cutoff were 93 and 94%, respectively. External validation of our riskcalculator showed a PA of 0.70. The application of our risk-calculator in the external validation cohort would have spared 66% of prostate biopsies at the cost of missing 8% of csPCa in the validation cohort.
CONCLUSIONS: An individual risk model was developed and externally validated relying on the largest available series of patients with PI-RADS 3 lesion at mpMRI. Using a 15% csPCa risk cut-off, our model would allow for a considerable reduction of prostate biopsies at the cost of missing a small number of csPCa cases.
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MP36-17 DEFINING BIOCHEMICAL RECURRENCE IN PROSTATE CANCER WITH HYBRID PSMA PET MRI
INTRODUCTION AND OBJECTIVES: Biochemical recurrence (BCR) can occur in in up to 50% or more of men with high risk prostate cancer previously treated with surgery of curative intent. Detection of locally recurrent or metastatic disease in the presence of BCR after treatment of localised disease at low prostate specific antigen (PSA) may be improved by use of hybrid Prostate Specific Membrane Antigen (PSMA), Positron Emission Tomography (PET) with magnetic resonance imaging (MRI). The clinical utility of this approach has been minimally reported. We sought to report on a large series of hybrid PSMA PET MRI in defining BCR.
METHODS: Following Institutional Research Board approval, a retrospective review of all PSMA PET MRI studies between April 2015 and April 2017 within a tertiary referral institution was conducted. Clinical variables, including patient demographics, PSA, previous treatment and histology prior to scan, indication for scan, imaging results, and outcome post imaging were collected prior to statistical analysis.
